diclofenac has been researched along with Carcinoma, Epidermoid in 28 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Laser therapy appears the best option among nonsurgical approaches for actinic cheilitis, and PDT showed higher efficacy when sequentially combined with 5% imiquimod." | 5.05 | Treatments of actinic cheilitis: A systematic review of the literature. ( Cornacchia, L; Lai, M; Longo, C; Pampena, R; Pellacani, G; Peris, K, 2020) |
| "AKs must be considered an early squamous cell carcinoma (SCC) for their probable progression into invasive SCC." | 2.66 | Current therapies for actinic keratosis. ( Conforti, C; Corneli, P; di Meo, N; Dianzani, C; Farinazzo, E; Giuffrida, R; Magaton Rizzi, G; Moret, A; Zalaudek, I, 2020) |
| "Chemoprevention of nonmelanoma skin cancer should be considered in patients likely to develop numerous, invasive, or metastatic nonmelanoma skin cancers." | 2.61 | Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. ( Council, ML; Nemer, KM, 2019) |
| "Actinic keratosis is currently believed to be an early stage in the evolution of squamous cell carcinoma." | 2.42 | Topical and light-based treatments for actinic keratoses. ( Alam, M; Goldberg, LH; Silapunt, S, 2003) |
| "The wool hydrolysates decreased squamous cell carcinoma cells viability by up to 67% comparing to untreated cells." | 1.46 | The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment. ( Borkowska, JK; Czuwara, J; Damps, T; Konop, M; Kowalkowski, T; Laskowska, AK; Misicka, A; Prokopowicz, M; Puszko, AK; Różycki, K; Rudnicka, L; Sosnowski, P, 2017) |
| "The intraoperative use of NSAIDs in breast cancer patients (Centre 1) is associated with a reduced recurrence rate (HR = 0." | 1.39 | Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. ( Berliere, M; Canon, JL; Coulie, PG; De Kock, M; Forget, P; Kremer, Y; Legrand, C; Machiels, JP; Poncelet, AJ; Stainier, A; Tombal, B, 2013) |
| "Non-melanoma skin cancer (NMSC) is the most common type of skin cancer in Caucasian populations." | 1.39 | Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis. ( Afaq, F; Arumugam, A; Athar, M; Chaudhary, SC; Elmets, CA; Kopelovich, L; Talwelkar, SS; Weng, Z, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 18 (64.29) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Lai, M | 1 |
| Pampena, R | 1 |
| Cornacchia, L | 1 |
| Pellacani, G | 3 |
| Peris, K | 3 |
| Longo, C | 1 |
| Gollnick, H | 1 |
| Dirschka, T | 1 |
| Ostendorf, R | 1 |
| Kerl, H | 1 |
| Kunstfeld, R | 1 |
| Collins, A | 1 |
| Savas, J | 1 |
| Doerfler, L | 1 |
| Dianzani, C | 1 |
| Conforti, C | 1 |
| Giuffrida, R | 1 |
| Corneli, P | 1 |
| di Meo, N | 1 |
| Farinazzo, E | 1 |
| Moret, A | 1 |
| Magaton Rizzi, G | 1 |
| Zalaudek, I | 1 |
| Tolley, K | 1 |
| Argenziano, G | 1 |
| Calzavara-Pinton, PG | 1 |
| Larsson, T | 1 |
| Ryttig, L | 1 |
| Damps, T | 1 |
| Laskowska, AK | 1 |
| Kowalkowski, T | 1 |
| Prokopowicz, M | 1 |
| Puszko, AK | 1 |
| Sosnowski, P | 1 |
| Czuwara, J | 1 |
| Konop, M | 1 |
| Różycki, K | 1 |
| Borkowska, JK | 1 |
| Misicka, A | 1 |
| Rudnicka, L | 1 |
| Wollina, U | 1 |
| Gaber, B | 1 |
| Koch, A | 1 |
| Tampucci, S | 1 |
| Carpi, S | 1 |
| Digiacomo, M | 1 |
| Polini, B | 1 |
| Fogli, S | 1 |
| Burgalassi, S | 1 |
| Macchia, M | 1 |
| Nieri, P | 1 |
| Manera, C | 1 |
| Monti, D | 1 |
| Nemer, KM | 1 |
| Council, ML | 1 |
| Forget, P | 1 |
| Machiels, JP | 1 |
| Coulie, PG | 1 |
| Berliere, M | 1 |
| Poncelet, AJ | 1 |
| Tombal, B | 1 |
| Stainier, A | 1 |
| Legrand, C | 1 |
| Canon, JL | 1 |
| Kremer, Y | 1 |
| De Kock, M | 1 |
| Peserico, A | 2 |
| Neri, L | 2 |
| Calzavara Pinton, P | 2 |
| Catricalà, C | 2 |
| Pimpinelli, N | 2 |
| Arumugam, A | 1 |
| Weng, Z | 1 |
| Talwelkar, SS | 1 |
| Chaudhary, SC | 1 |
| Kopelovich, L | 1 |
| Elmets, CA | 1 |
| Afaq, F | 1 |
| Athar, M | 1 |
| Mücke, T | 1 |
| Gentz, I | 1 |
| Kanatas, A | 1 |
| Ritschl, LM | 1 |
| Mitchell, DA | 1 |
| Wolff, KD | 1 |
| Deppe, H | 1 |
| Ulrich, C | 1 |
| Fecker, LF | 2 |
| Stockfleth, E | 2 |
| Braun, FK | 1 |
| Rodust, PM | 2 |
| Schwarz, C | 1 |
| Köhler, A | 1 |
| Leverkus, M | 1 |
| Eberle, J | 2 |
| Shoimer, I | 1 |
| Rosen, N | 1 |
| Muhn, C | 1 |
| Fenske, NA | 1 |
| Spencer, J | 1 |
| Adam, F | 1 |
| Jadotte, YT | 1 |
| Schwartz, RA | 1 |
| Burns, EM | 1 |
| Tober, KL | 1 |
| Riggenbach, JA | 1 |
| Schick, JS | 1 |
| Lamping, KN | 1 |
| Kusewitt, DF | 1 |
| Young, GS | 1 |
| Oberyszyn, TM | 1 |
| Liebman, TN | 1 |
| Stein, JA | 1 |
| Polsky, D | 1 |
| Peterson, SR | 1 |
| Goldberg, LH | 2 |
| Del Rosso, JQ | 1 |
| Silapunt, S | 1 |
| Alam, M | 1 |
| Berman, B | 1 |
| Bienstock, L | 1 |
| Kuritzky, L | 1 |
| Mayeaux, EJ | 1 |
| Tyring, SK | 1 |
| Merk, HF | 1 |
| Newman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma[NCT01453179] | Phase 4 | 221 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for diclofenac and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Treatments of actinic cheilitis: A systematic review of the literature.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Cheilitis; Combined Modality Therapy; Dermabrasion; D | 2020 |
Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.
Topics: Adjuvants, Immunologic; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Dic | 2020 |
Nonsurgical Treatments for Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Anilides; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bi | 2019 |
Current therapies for actinic keratosis.
Topics: Aftercare; Carcinoma, Squamous Cell; Chemexfoliation; Cryotherapy; Curettage; Dermoscopy; Diclofenac | 2020 |
Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Carcinoma, Basal Cell; Carci | 2019 |
Topical treatment of field cancerization.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Diclofenac; Fluorouraci | 2009 |
Actinic keratoses: past, present and future.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamou | 2010 |
New and emerging topical approaches for actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Ster | 2003 |
Topical and light-based treatments for actinic keratoses.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminolevulinic Acid; Aminoquinolines; Antineoplasti | 2003 |
Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel.
Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Consens | 2006 |
Topical diclofenac in the treatment of actinic keratoses.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Diclofen | 2007 |
2 trials available for diclofenac and Carcinoma, Epidermoid
| Article | Year |
|---|---|
PHOTODYNAMIC TREATMENT WITH NANOEMULSIFIED 5-AMINOLEVULINIC ACID AND NARROW BAND RED LIGHT FOR FIELD CANCERIZATION DUE TO OCCUPATIONAL EXPOSURE TO ULTRAVIOLET LIGHT IRRADIATION.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Sq | 2018 |
Clinical trial analyzing the impact of continuous defocused CO2 laser vaporisation on the malignant transformation of erosive oral lichen planus.
Topics: Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Cell T | 2015 |
15 other studies available for diclofenac and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Pharmacoeconomic evaluations in the treatment of actinic keratoses.
Topics: Carcinoma, Squamous Cell; Diclofenac; Diterpenes; Economics, Pharmaceutical; Humans; Italy; Keratosi | 2017 |
The effect of wool hydrolysates on squamous cell carcinoma cells in vitro. Possible implications for cancer treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Diclofena | 2017 |
Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line; Cell Proliferation; Cell Survival; Diclofenac; Humans; | 2019 |
Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Non-Small-Cell | 2013 |
Key Opinion Leader (KOL) Consensus for actinic keratosis management in Italy: the AKTUAL Workshop.
Topics: Aminoquinolines; Carcinoma, Squamous Cell; Case Management; Clinical Trials as Topic; Cryosurgery; D | 2013 |
Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.
Topics: Animals; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2013 |
Physicians' opinions and clinical practice patterns for actinic keratosis management in Italy.
Topics: Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Attitude of Health | 2014 |
Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Squamous Cell; CASP8 and FADD-Like Ap | 2010 |
Current management of actinic keratoses.
Topics: Administration, Cutaneous; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic | 2010 |
Solar cheilosis: an ominous precursor part II. Therapeutic perspectives.
Topics: Administration, Topical; Aminoquinolines; Biopsy; Carcinoma, Squamous Cell; Cheilitis; Combined Moda | 2012 |
Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w.
Topics: Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; C | 2012 |
Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma.
Topics: Administration, Topical; Animals; Carcinoma, Squamous Cell; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2013 |
Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
New and emerging treatments for nonmelanomas and actinic keratoses.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Basal C | 2003 |
Upper gastrointestinal bleeding following major maxillofacial surgery.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carcinoma, Squamous Cell; Chemopre | 1997 |